Moreover, germline mutations in the breast cancer susceptibility gene 1 (BRCA1) considerably increase the risk of breast and ovarian cancers and, thus, modulation of PTEN/BRCA1 proteins may prove therapeutically beneficial for breast, ovarian, and prostate cancer treatment [72]. This evidence concerns the gene BRCA1 and prostate cancer.